Scott W. Morrison
Known title: DirectorCIK: 0001662426
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Tarsus Reports XDEMVY Revenue and Option‑Style Retina Deals. The article notes that Tarsus’s drug XDEMVY is now generating revenue to cover operating costs. It also explains that the company’s retina product deals are structured like options, potentially providing flexible upside. These developments may improve the company’s cash flow outlook and support future growth initiatives.
Transaction History
| ZLAB | ▲ Buy | Grant | 22,371 | $0 | 6/17/2026 | View on chart |
| TARS | ▲ Buy | Option Exercise | 2,954 | — | 6/12/2026 | View on chart |
| TARS | ▲ Buy | Option Exercise | 1,334 | — | 9/15/2025 | View on chart |
| ZLAB | ▲ Buy | Grant | 10,831 | $0 | 6/18/2025 | View on chart |
| TARS | ▲ Buy | Option Exercise | 3,350 | — | 6/13/2025 | View on chart |
| ZLAB | ▼ Sell | Open Market | 23,799 | $715K | 5/9/2025 | View on chart |
| TARS | ▼ Sell | Gift | 6,016 | $0 | 9/30/2024 | View on chart |
| TARS | ▲ Buy | Option Exercise | 1,333 | — | 9/15/2024 | View on chart |
| TARS | ▲ Buy | Option Exercise | 3,350 | — | 6/24/2024 | View on chart |
| ZLAB | ▲ Buy | Grant | 21,253 | $0 | 6/18/2024 | View on chart |
| TARS | ▲ Buy | Option Exercise | 1,333 | — | 9/15/2023 | View on chart |
| ZLAB | ▲ Buy | Grant | 18,903 | $500K | 6/29/2023 | View on chart |
| ZLAB | ▲ Buy | Grant | 7,345 | $0 | 10/18/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Zai Lab Releases Q2 2026 Earnings and Call Transcript
Zai Lab has published its second-quarter 2026 financial results along with the full earnings call transcript. This update provides investors with the latest details on the company's performance and strategic outlook. The stock is currently trading within its 52-week range, with analysts maintaining a wide target price spread.
Zai Lab Releases Q2 2026 Earnings and Call Transcript. Zai Lab has published its second-quarter 2026 financial results along with the full earnings call transcript. This update provides investors with the latest details on the company's performance and strategic outlook. The stock is currently trading within its 52-week range, with analysts maintaining a wide target price spread.